GRP78 enabled micelle-based glioma targeted drug delivery

Area of Science:

• Oncology
• Biotechnology
• Drug Delivery

Background:

• Glucose-regulated protein 78 (GRP78) is a cancer cell-surface marker involved in tumor progression and drug resistance.
• Tumor-homing peptides like l-VAP show promise for targeting GRP78 but suffer from rapid clearance and degradation.
• Developing more stable peptides is crucial for effective targeted cancer therapy.

Purpose of the Study:

• To design and evaluate novel, stable d-isomeric peptides (RI-VAP and d-VAP) for enhanced glioma targeting.
• To assess the in vivo tumor accumulation and therapeutic efficacy of these d-peptides.
• To investigate the potential of VAP-modified micelles for targeted paclitaxel delivery in glioma.

Main Methods:

• Structure-guided peptide design and retro-inverso isomerization were used to create RI-VAP and d-VAP.
• In vitro binding affinity to GRP78 was experimentally confirmed.
• In vivo imaging tracked tumor accumulation, and anti-tumor efficacy was evaluated using paclitaxel-loaded micelles.

Main Results:

• RI-VAP and d-VAP demonstrated comparable binding affinity to GRP78 as l-VAP.
• In vivo imaging revealed significantly improved tumor accumulation for RI-VAP and d-VAP compared to l-VAP.
• Paclitaxel-loaded micelles modified with RI-VAP or d-VAP showed superior anti-tumor efficacy against glioma.

Conclusions:

• Stable d-isomeric VAP peptides (RI-VAP, d-VAP) effectively target GRP78-overexpressing gliomas.
• VAP-modified micelles enhance paclitaxel delivery and anti-tumor efficacy for glioma treatment.
• These findings highlight the therapeutic potential of stable VAP peptides in targeted cancer drug delivery.